HOOK - HOOKIPA Pharma Inc.

1.0325
0.002   0.242%

Share volume: 18,948
Last Updated: 03-05-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.26%

PREVIOUS CLOSE
CHG
CHG%
$1.03
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
0%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 0%
Performance
5 Days
-0.72%
1 Month
0.24%
3 Months
19.01%
6 Months
13.46%
1 Year
13.46%
2 Year
13.46%
Key data
Stock price
$1.03
P/E Ratio 
N/A
DAY RANGE
$1.01 - $1.05
EPS 
N/A
52 WEEK RANGE
$0.84 - $1.08
52 WEEK CHANGE
$13.46
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$7,114
AVERAGE 30 VOLUME 
$5,556
Company detail
CEO: Jörn Aldag
Region: US
Website: www.hookipapharma.com
Employees: 160
IPO year: 2025
Issue type:
Market: OTCM
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

HOOKIPA Pharma Inc. develops immunotherapeutics targeting infectious diseases and cancers. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers.

Recent news